The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Critical Challenges in PD: Postural Instability and Gait Dis, 2012Targeted Cognitive Training Program for Freezing of Gait
Promising Outcomes of Original Grant:
In our original study we investigated the processes underlying the freezing phenomenon in PD. In this work we found symptoms of freezing of gait (FOG) could be... -
Target Validation, 2011The Sigma 1 Receptor as a Target for Disease-modifying Therapies in Parkinson's Disease
Objective/Rationale:
The Sigma-1 receptor (Sig-1R) is a protein involved in the transport of lipids and proteins between organelles within the cell. Impairment of these intracellular trafficking... -
Target Validation, 2011Validation of Dorsal Column Electrical Stimulation as a Target for Parkinson's Disease Therapy
Objective/Rationale:
Direct electrical stimulation of certain areas of the brain is an effective method to treat the motor symptoms of Parkinson’s, but it requires the insertion of electrodes into the... -
Target Validation, 2011Lamp-2a as a Therapeutic Target in Parkinson's Disease
Objective/Rationale:
Multiple pieces of evidence converge on the notion that accumulation of the protein alpha-synuclein is important for Parkinson’s disease (PD) pathogenesis. One of the ways through... -
Antibody Comparison, 2011LRRK2 Immunocytochemistry in Cultured Neurons
Objective/Rationale:
Several antibodies have been identified that recognize Leucine-Rich Repeat Kinase 2 (LRRK2), but uncertainty persists as to whether such antibodies are reliable in detecting ... -
Antibody Comparison, 2011Characterization of LRRK2 Monoclonal Antibodies in Pre-clinical Brain Tissue
Objective/Rationale:
Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are implicated in Parkinson’s disease in humans. At present we understand neither the normal nor the pathogenic role of LRRK2. We...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.